NCT01918683Active, not recruiting
TACE With or Without SBRT as Bridging Therapy for Pre-transplant HCC Patients
A Pilot Trial of Transarterial Chemoembolization With or Without Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma Patients Awaiting Liver Transplantation
Source: ClinicalTrials.gov · Last updated 29 Jan 2026
Brief summary (registry, in English)
This trial is designed to be the initial prospective pilot investigation of the effectiveness of combined SBRT and TACE as bridging therapy for HCC patients awaiting liver transplanation. No prospective clinical trials regarding the combination of TACE and SBRT in pre-transplant population have been performed. We propose the trial be conducted as a pilot clinical trial with the goal of enrolling 40 patients into each arm
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 7 Aug 2013
- Start date
- 1 Jul 2013
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT01918683
What you commit to
- Study type: Interventional
- Planned participants: 40
- From 1 Jul 2013 to the primary completion date, 31 Dec 2026
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior radiotherapy to the upper abdomen or radioembolization of the liver
- Prior TACE to the target lesion, RFA, or liver transplant
- Ascites refractory to medical therapy
- Contraindication to receiving radiotherapy or TACE
- Participation in another concurrent treatment protocol
Other illness
- Active GI ulcer disease within 4 weeks of study enrollment
Other
- Active GI bleed within 2 weeks of study enrollment
- Complete obstruction of portal venous flow to the segment of liver that includes the target lesion
- Contraindication to both contrast enhanced MRI and contrast enhanced CT (i.e. unable to undergo follow-up imaging or SBRT treatment planning)
- Women who are pregnant
Who the study is looking for
- Patient capable of giving informed consent
- Patient diagnosed with hepatocellular carcinoma and listed or recommended to be listed for orthotopic liver transplantation at the participating institution
- Age \> 18 years old
- Meets clinical criteria for eligibility for TACE to the target lesion per Interventional Radiology
- Childs' Class A or B7
- Eastern Clinical Oncology Group performance status 0 or 1
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Loyola University Medical Center Coordinator of this site? Confirm its status | Maywood | United States | Unknown status |
| Abramson Cancer Center of the University of Pennsylvania Coordinator of this site? Confirm its status | Philadelphia | United States | Unknown status |
| Oregon Health Science University Coordinator of this site? Confirm its status | Portland | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.